Skip to content
OpenCapital
Get started

Geron GERN AFS and Trading Securities - Unrealized Loss Position (>=12 Months)

AFS and Trading Securities - Unrealized Loss Position (>=12 Months) at other companies

Tango Therapeutics logo
Tango TherapeuticsTNGX
——
Exelixis logo
ExelixisEXEL
——

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's afs and trading securities - unrealized loss position (>=12 months).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's AFS and trading securities - unrealized loss position (>=12 months)?
Geron (GERN) reported AFS and trading securities - unrealized loss position (>=12 months) of $0 in Q1 2026.
How has Geron's AFS and trading securities - unrealized loss position (>=12 months) changed year-over-year?
Geron's AFS and trading securities - unrealized loss position (>=12 months) decreased by 100.0% year-over-year, from $2M to $0.